Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8728096 | 0.93 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1GPR84 | |
| SCHEMBL8727473 | 0.93 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1GPR84 | |
| SCHEMBL31522342 | 0.90 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1GPR84 | |
| SCHEMBL6818957 | 0.90 | ITGB3 (0.51) | ITGB3ITGA2BITGAVNOD1GPR84 | |
| SCHEMBL8760082 | 0.88 | ITGB3 (0.53) | ITGB3ITGA2BITGAVNOD1MMP2 | |
| SCHEMBL8747398 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BITGAVMMP2MMP9 | |
| SCHEMBL7395698 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BITGAVMMP2MMP9 | |
| SCHEMBL7144029 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BITGAVMMP2MMP9 | |
| SCHEMBL7144039 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BITGAVMMP2MMP9 | |
| SCHEMBL7118389 | 0.82 | ITGB3 (0.52) | ITGB3ITGA2BITGAVNOD1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | claimed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-7521464-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | ITGB3 4692/4885ITGA2B 4772/4885ITGAV 4827/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | ITGB3 4125/4885ITGA2B 4331/4885ITGAV 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.